Markets
News
Analysis
User
24/7
Economic Calendar
Education
Data
- Names
- Latest
- Prev
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
A:--
F: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
A:--
F: --
P: --
A:--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
No matching data
Latest Views
Latest Views
Trending Topics
To quickly learn market dynamics and follow market focuses in 15 min.
In the world of mankind, there will not be a statement without any position, nor a remark without any purpose.
Inflation, exchange rates, and the economy shape the policy decisions of central banks; the attitudes and words of central bank officials also influence the actions of market traders.
Money makes the world go round and currency is a permanent commodity. The forex market is full of surprises and expectations.
Top Columnists
Enjoy exciting activities, right here at FastBull.
The latest breaking news and the global financial events.
I have 5 years of experience in financial analysis, especially in aspects of macro developments and medium and long-term trend judgment. My focus is maily on the developments of the Middle East, emerging markets, coal, wheat and other agricultural products.
BeingTrader chief Trading Coach & Speaker, 8+ years of experience in the forex market trading mainly XAUUSD, EUR/USD, GBP/USD, USD/JPY, and Crude Oil. A confident trader and analyst who aims to explore various opportunities and guide investors in the market. As an analyst I am looking to enhance the trader’s experience by supporting them with sufficient data and signals.
Latest Update
Risk Warning on Trading HK Stocks
Despite Hong Kong's robust legal and regulatory framework, its stock market still faces unique risks and challenges, such as currency fluctuations due to the Hong Kong dollar's peg to the US dollar and the impact of mainland China's policy changes and economic conditions on Hong Kong stocks.
HK Stock Trading Fees and Taxation
Trading costs in the Hong Kong stock market include transaction fees, stamp duty, settlement charges, and currency conversion fees for foreign investors. Additionally, taxes may apply based on local regulations.
HK Non-Essential Consumer Goods Industry
The Hong Kong stock market encompasses non-essential consumption sectors like automotive, education, tourism, catering, and apparel. Of the 643 listed companies, 35% are mainland Chinese, making up 65% of the total market capitalization. Thus, it's heavily influenced by the Chinese economy.
HK Real Estate Industry
In recent years, the real estate and construction sector's share in the Hong Kong stock index has notably decreased. Nevertheless, as of 2022, it retains around 10% market share, covering real estate development, construction engineering, investment, and property management.
Hongkong, China
Ho Chi Minh, Vietnam
Dubai, UAE
Lagos, Nigeria
Cairo, Egypt
White Label
Data API
Web Plug-ins
Affiliate Program
View All
No data
Not Logged In
Log in to access more features
FastBull Membership
Not yet
Purchase
Log In
Sign Up
Hongkong, China
Ho Chi Minh, Vietnam
Dubai, UAE
Lagos, Nigeria
Cairo, Egypt
White Label
Data API
Web Plug-ins
Affiliate Program
Sept 17 (Reuters) - Liquidia Corp LQDA.O:
LIQUIDIA CORP: UNITED THERAPEUTICS FILED NEW CROSS-CLAIMS IN FDA SUIT AGAINST FDA, RE-ASSERTING CHALLENGE TO FDA'S ACCEPTANCE OF CO'S YUTREPIA NDA
LIQUIDIA- INTENDS TO DEFEND ITS ABILITY TO LAUNCH YUTREPIA & TO DEFEND ITSELF AGAINST UNITED'S ALLEGATIONS
Source text for Eikon: [ID:n0001104659-24-100714]
Further company coverage: LQDA.O
Reporter Name | Edgemond James |
Relationship | CFO AND TREASURER |
Type | Sell |
Amount | $2,648,527 |
SEC Filing | Form 4 |
James Edgemond, CFO and Treasurer of United Therapeutics Corp, sold 7,810 shares of common stock on September 16, 2024, at a price of $339.12 per share, totaling $2,648,527. Following these transactions, Edgemond directly owns 3,740 shares of the company. The sales were executed under a Rule 10b5-1 trading plan established on May 17, 2024.
SEC Filing: UNITED THERAPEUTICS Corp [ UTHR ] - Form 4 - Sep. 17, 2024
Travere Therapeutics (TVTX) shares rallied 5.9% in the last trading session to close at $14.27. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 55.3% gain over the past four weeks.
The company markets Filspari (sparsentan), an oral non-immunosuppressive drug approved for treating IgA nephropathy (IgAN), a rare kidney disease. Filspari has seen strong market demand, generating $47 million in sales in the first half of 2024. Last week, the FDA granted full approval for Filspari to treat primary IgAN in adults who are at high/low risk of disease progression, making it the only non-immunosuppressive drug available for this condition. This approval expands the potential patient base and sales opportunities, which may have contributed to a recent rise in the company’s share price.
This drug developer is expected to post quarterly loss of $0.71 per share in its upcoming report, which represents a year-over-year change of +39.3%. Revenues are expected to be $59.23 million, up 59.7% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Travere, the consensus EPS estimate for the quarter has been revised 1.1% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on TVTX going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold).
Travere belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Liquidia Technologies, Inc. (LQDA), closed the last trading session 2.1% higher at $10. Over the past month, LQDA has returned -30.6%.
Liquidia Technologies' consensus EPS estimate for the upcoming report has changed -11.5% over the past month to -$0.38. Compared to the company's year-ago EPS, this represents a change of -58.3%. Liquidia Technologies currently boasts a Zacks Rank of #3 (Hold).
Zacks Investment Research
NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Paragon 28, Inc. (NYSE: FNA), Centuri Holdings, Inc (NYSE: CTRI), Liquidia Corporation (NASDAQ: LQDA), and Elastic N.V. (NYSE: ESTC). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.
Paragon 28, Inc. (NYSE: FNA)
On July 30, 2024, after the market closed, Paragon 28 filed a current report on Form 8-K with the SEC. It stated that “On July 30, 2024, the Audit Committee of the Board of Directors (the “Audit Committee”) of Paragon 28, Inc. (the “Company”), in consultation with management, concluded that the Company’s previously issued audited consolidated financial statements for the fiscal year ended December 31, 2023, contained within the Annual Report on Form 10-K for that year (and the associated audit report of the Company’s independent registered accounting firm) and the unaudited condensed consolidated financial statements contained within the Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2023, June 30, 2023, September 30, 2023, and March 31, 2024 should no longer be relied upon due to errors in such financial statements, and therefore a restatement of these prior financial statements is required. Accordingly, the Company intends to restate the aforementioned financial statements by amending its Annual Report on Form 10-K for the year ended December 31, 2023 and its quarterly report on Form 10-Q for the quarter ended March 31, 2024 (the “Restated Filings”) as soon as reasonably practicable.”
On this news, the price of Paragon 28 stock fell by 13.7% on July 31, 2024.
For more information on the Paragon 28 investigation go to: https://bespc.com/cases/FNA
Centuri Holdings, Inc. (NYSE: CTRI)
On July 29, 2024, Centuri reported its financial results for the second quarter, revealing a Non-GAAP Earnings Per Share (EPS) of $0.20, which falls short by $0.02 in comparison to market expectations. Additionally, the company's revenue for the quarter was disclosed at $643.39 million, representing a year-over-year decline of 17.0%, and missing analyst projections by $117.03 million.
Just months earlier on April 18, 2024, Centuri conducted its initial public offering ("IPO"), and the company sold 12.4 million shares for $21. Since the IPO, the stock has plummeted and on July 29, 2024, Centuri stock closed at $15.72.
For more information on the Centuri investigation go to: https://bespc.com/cases/CTRI
Liquidia Corporation (NASDAQ: LQDA)On August 19, 2024, Liquidia issued a press release announcing that "the U.S. Food and Drug Administration (FDA) has granted tentative approval of YUTREPIA™ (treprostinil) inhalation powder to treat adults with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD)" but "must await the expiration of regulatory exclusivity of a competing product before final approval can be granted."
On this news, Liquidia's stock price fell $4.32 per share, or 30.62%, to close at $9.79 per share on August 19, 2024.
For more information on the Liquidia investigation go to: https://bespc.com/cases/LQDA
Elastic N.V. (NYSE: ESTC)
On August 30, 2024, Elastic announced that it was reducing its revenue forecast for the year, a move that prompted a flurry of downgrades from market analysts. A major concern was the disruption within the sales organization, which appeared during a period of strategic realignment aimed at improving sales efficiency and effectiveness. Moreover, the company has been facing a decrease in demand across the regions of Europe, the Middle East, and Africa, further complicating its financial outlook.
Following this news, Elastic's stock was trading significantly lower in pre-market trading on August 30, 2024.
For more information on the Elastic investigation go to: https://bespc.com/cases/ESTC
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact Information:
Bragar Eagel & Squire, P.C.Brandon Walker, Esq. Marion Passmore, Esq.(212) 355-4648investigations@bespc.comwww.bespc.com
White Label
Data API
Web Plug-ins
Poster Maker
Affiliate Program
The risk of loss in trading financial instruments such as stocks, FX, commodities, futures, bonds, ETFs and crypto can be substantial. You may sustain a total loss of the funds that you deposit with your broker. Therefore, you should carefully consider whether such trading is suitable for you in light of your circumstances and financial resources.
No decision to invest should be made without thoroughly conducting due diligence by yourself or consulting with your financial advisors. Our web content might not suit you since we don't know your financial conditions and investment needs. Our financial information might have latency or contain inaccuracy, so you should be fully responsible for any of your trading and investment decisions. The company will not be responsible for your capital loss.
Without getting permission from the website, you are not allowed to copy the website's graphics, texts, or trademarks. Intellectual property rights in the content or data incorporated into this website belong to its providers and exchange merchants.